X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 51 filers reported holding X4 PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $33,082 | -43.8% | 30,350 | 0.0% | 0.00% | – |
Q2 2023 | $58,879 | +123.0% | 30,350 | 0.0% | 0.00% | – |
Q1 2023 | $26,405 | -14.4% | 30,350 | -2.3% | 0.00% | – |
Q4 2022 | $30,840 | -41.8% | 31,057 | 0.0% | 0.00% | – |
Q3 2022 | $53,000 | +165.0% | 31,057 | +47.5% | 0.00% | – |
Q2 2022 | $20,000 | +5.3% | 21,057 | +90.4% | 0.00% | – |
Q1 2022 | $19,000 | -20.8% | 11,057 | +6.8% | 0.00% | – |
Q4 2021 | $24,000 | -56.4% | 10,350 | 0.0% | 0.00% | – |
Q3 2021 | $55,000 | -17.9% | 10,350 | 0.0% | 0.00% | – |
Q2 2021 | $67,000 | -24.7% | 10,350 | 0.0% | 0.00% | – |
Q1 2021 | $89,000 | +32.8% | 10,350 | 0.0% | 0.00% | – |
Q4 2020 | $67,000 | -4.3% | 10,350 | 0.0% | 0.00% | – |
Q3 2020 | $70,000 | -27.1% | 10,350 | 0.0% | 0.00% | – |
Q2 2020 | $96,000 | -7.7% | 10,350 | 0.0% | 0.00% | – |
Q1 2020 | $104,000 | -6.3% | 10,350 | 0.0% | 0.00% | – |
Q4 2019 | $111,000 | 0.0% | 10,350 | +19.0% | 0.00% | – |
Q3 2019 | $111,000 | -4.3% | 8,700 | +13.0% | 0.00% | – |
Q2 2019 | $116,000 | – | 7,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
RA Capital Management | 559,494 | $3,788,000 | 0.07% |
Bleichroeder LP | 35,730 | $242,000 | 0.04% |